drugset

drugset / Trial / NCT00163098

A Study of UK-369,003 on the Safety and Efficacy in Patients With COPD

NCT00163098 ↗

Phase 1/2 Completed 136 enrolled Pfizer

RandomizedParallel-groupDouble-blindTreatment

Summary

A randomised, controlled study investigating the effect of UK-369,003 on exercise tolerance in patients with COPD

Timeline

Start: 2004-12
Primary completion: —
Completion: 2005-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	GISADENAFIL	Small molecule	—	—

Indications